The DOI matches its Crossref record; 340 of the 340 references it cites were found in a registry or an index.
Therapeutic strategies to overcome taxane resistance in cancer
Abstract
One of the primary causes of attenuated or loss of efficacy of cancer chemotherapy is the emergence of multidrug resistance (MDR). Numerous studies have been published regarding potential approaches to reverse resistance to taxanes, including paclitaxel (PTX) and docetaxel, which represent one of the most important classes of anticancer drugs. Since 1984, following the FDA approval of paclitaxel for the treatment of advanced ovarian carcinoma, taxanes have been extensively used as drugs that target tumor microtubules. Taxanes, have been shown to affect an array of oncogenic signaling pathways and have potent cytotoxic efficacy. However, the clinical success of these drugs has been restricted by the emergence of cancer cell resistance, primarily caused by the overexpression of MDR efflux transporters or by microtubule alterations. In vitro and in vivo studies indicate that the mechanisms underlying the resistance to PTX and docetaxel are primarily due to alterations in α-tubulin and β-tubulin. Moreover, resistance to PTX and docetaxel results from: 1) alterations in microtubule-protein interactions, including microtubule-associated protein 4, stathmin, centriole, cilia, spindle-associated protein, and kinesins; 2) alterations in the expression and activity of multidrug efflux transporters of the ABC superfamily including P-glycoprotein (P-gp/ABCB1); 3) overexpression of anti-apoptotic proteins or inhibition of apoptotic proteins and tumor-suppressor proteins, as well as 4) modulation of signal transduction pathways associated with the activity of several cytokines, chemokines and transcription factors. In this review, we discuss the abovementioned molecular mechanisms and their role in mediating cancer chemoresistance to PTX and docetaxel. We provide a detailed analysis of both in vitro and in vivo experimental data and describe the application of these findings to therapeutic practice. The current review also discusses the efficacy of different pharmacological modulations to achieve reversal of PTX resistance. The therapeutic roles of several novel compounds, as well as herbal formulations, are also discussed. Among them, many structural derivatives had efficacy against the MDR phenotype by either suppressing MDR or increasing the cytotoxic efficacy compared to the parental drugs, or both. Natural products functioning as MDR chemosensitizers offer novel treatment strategies in patients with chemoresistant cancers by attenuating MDR and increasing chemotherapy efficacy. We broadly discuss the roles of inhibitors of P-gp and other efflux pumps, in the reversal of PTX and docetaxel resistance in cancer cells and the significance of using a nanomedicine delivery system in this context. Thus, a better understanding of the molecular mechanisms mediating the reversal of drug resistance, combined with drug efficacy and the application of target-based inhibition or specific drug delivery, could signal a new era in modern medicine that would limit the pathological consequences of MDR in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
Natural products: A continuing source of novel drug leads
Cragg, G. M., & Newman, D. J. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.02.008 · Cited by 2,906
The re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
NF-κB in cancer: from innocent bystander to major culprit
Karin, M., Cao, Y., Greten, F. R., & Li, Z.-W. (2002) · Nature Reviews Cancer · doi:10.1038/nrc780 · Cited by 2,478
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
Apoptosis: A Target for Anticancer Therapy
Pfeffer, C., & Singh, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020448 · Cited by 1,542
The IKK NF-κB system: a treasure trove for drug development
Karin, M., Yamamoto, Y., & Wang, Q. M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1279 · Cited by 1,364
Microtubules and resistance to tubulin-binding agents
Kavallaris, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2803 · Cited by 1,120
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
The hypoxic tumour microenvironment
Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G., & Amelio, I. (2018) · Oncogenesis · doi:10.1038/s41389-017-0011-9 · Cited by 1,019
Nurgali, K., Jagoe, R. T., & Abalo, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00245 · Cited by 1,017
The tubulin code and its role in controlling microtubule properties and functions
Janke, C., & Magiera, M. M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0214-3 · Cited by 956
Control of microtubule organization and dynamics: Two ends in the limelight
Akhmanova, A., & Steinmetz, M. O. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4084 · Cited by 895
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
Anand, U., Jacobo-Herrera, N., Altemimi, A., & Lakhssassi, N. (2019) · Metabolites · doi:10.3390/metabo9110258 · Cited by 867
Self-citationSensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W., Anderson, D. J., Helgason, E., Ernst, J. A., Eby, M., Liu, J., et al. (2011) · Nature · doi:10.1038/nature09779 · Cited by 794
Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z.-S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 777
Self-citationCancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
The epidermal growth factor receptor family: Biology driving targeted therapeutics
Wieduwilt, M. J., & Moasser, M. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7440-8 · Cited by 751
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., & Giannakakou, P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00077-1 · Cited by 730
Mechanisms of Action of Bcl-2 Family Proteins
Shamas-Din, A., Kale, J., Leber, B., & Andrews, D. W. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008714 · Cited by 705
BCL-2 family isoforms in apoptosis and cancer
Warren, C. F. A., Wong-Brown, M. W., & Bowden, N. A. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1407-6 · Cited by 700
Alushin, G. M., Lander, G. C., Kellogg, E. H., Zhang, R., Baker, D., & Nogales, E. (2014) · Cell · doi:10.1016/j.cell.2014.03.053 · Cited by 696
Plant-derived anticancer agents: A green anticancer approach
Iqbal, J., Abbasi, B. A., Mahmood, T., Kanwal, S., Ali, B., Shah, S. A., & Khalil, A. T. (2017) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2017.10.016 · Cited by 685
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Self-citationResistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., et al. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0221-1 · Cited by 665
Autophagy and multidrug resistance in cancer
Li, Y.-J., Lei, Y.-H., Yao, N., Wang, C.-R., Hu, N., Ye, W.-C., Zhang, D.-M., & Chen, Z.-S. (2017) · Chinese Journal of Cancer · doi:10.1186/s40880-017-0219-2 · Cited by 665
Self-citationModulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Self-citationHIF-1α induces cell cycle arrest by functionally counteracting Myc
Koshiji, M., Kageyama, Y., Pete, E. A., Horikawa, I., Barrett, J. C., & Huang, L. E. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600196 · Cited by 652
Role of p53 in Cell Death and Human Cancers
Ozaki, T., & Nakagawara, A. (2011) · Cancers · doi:10.3390/cancers3010994 · Cited by 650
SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction
Inuzuka, H., Shaik, S., Onoyama, I., Gao, D., Tseng, A., Maser, R. S., Zhai, B., Wan, L., Gutierrez, A., Lau, A. W., et al. (2011) · Nature · doi:10.1038/nature09732 · Cited by 632
Role of Tau as a Microtubule-Associated Protein: Structural and Functional Aspects
Barbier, P., Zejneli, O., Martinho, M., Lasorsa, A., Belle, V., Smet-Nocca, C., Tsvetkov, P. O., Devred, F., & Landrieu, I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00204 · Cited by 617
Multiple Forms of Tubulin: Different Gene Products and Covalent Modifications
Ludueña, R. F. (1997) · International Review of Cytology · doi:10.1016/s0074-7696(08)62138-5 · Cited by 611
Kavallaris, M., Kuo, D. Y., Burkhart, C. A., Regl, D. L., Norris, M. D., Haber, M., & Horwitz, S. B. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119642 · Cited by 601
The challenge of drug resistance in cancer treatment: a current overview
Nikolaou, M., Pavlopoulou, A., Georgakilas, A. G., & Kyrodimos, E. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9903-0 · Cited by 600
Williamson, G., Kay, C. D., & Crozier, A. (2018) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12351 · Cited by 591
Microtubules and Microtubule-Associated Proteins
Goodson, H. V., & Jonasson, E. M. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022608 · Cited by 579
ErbB receptors: from oncogenes to targeted cancer therapies
Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., & Greene, M. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32278 · Cited by 574
Targeting Microtubules by Natural Agents for Cancer Therapy
Mukhtar, E., Adhami, V. M., & Mukhtar, H. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0791 · Cited by 565
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy
von Karstedt, S., Montinaro, A., & Walczak, H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.28 · Cited by 556
Targeting BCL-2 regulated apoptosis in cancer
Campbell, K. J., & Tait, S. W. G. (2018) · Open Biology · doi:10.1098/rsob.180002 · Cited by 545
Improving drug delivery to solid tumors: Priming the tumor microenvironment
Khawar, I. A., Kim, J. H., & Kuh, H.-J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.018 · Cited by 533
Predicting drug sensitivity and resistance
Szakács, G., Annereau, J.-P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K. J., Reinhold, W., Guo, Y., Kruh, G. D., Reimers, M., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.026 · Cited by 531
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Self-citationHypoxia-Inducible Factor 1α Is Essential for Cell Cycle Arrest during Hypoxia
Goda, N., Ryan, H. E., Khadivi, B., McNulty, W., Rickert, R. C., & Johnson, R. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.359-369.2003 · Cited by 520
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.003 · Cited by 504
Self-citationHypoxia-Modified Cancer Cell Metabolism
Al Tameemi, W., Dale, T. P., Al-Jumaily, R. M. K., & Forsyth, N. R. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00004 · Cited by 503
Dai, D., Zeldin, D. C., Blaisdell, J. A., Chanas, B., Coulter, S. J., Ghanayem, B. I., & Goldstein, J. A. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00006 · Cited by 494
Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents
Prota, A. E., Bargsten, K., Zurwerra, D., Field, J. J., Díaz, J. F., Altmann, K.-H., & Steinmetz, M. O. (2013) · Science · doi:10.1126/science.1230582 · Cited by 489
Lysosomes as mediators of drug resistance in cancer
Zhitomirsky, B., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.004 · Cited by 482
Self-citationGiannakakou, P., Gussio, R., Nogales, E., Downing, K. H., Zaharevitz, D., Bollbuck, B., Poy, G., Sackett, D., Nicolaou, K. C., & Fojo, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040546297 · Cited by 477
Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?
Callaghan, R., Luk, F., & Bebawy, M. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.056176 · Cited by 453
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.
Ozols, R. F., Cunnion, R. E., Klecker, R. W., Hamilton, T. C., Ostchega, Y., Parrillo, J. E., & Young, R. C. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.4.641 · Cited by 426
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
Glaser, S. P., Lee, E. F., Trounson, E., Bouillet, P., Wei, A., Fairlie, W. D., Izon, D. J., Zuber, J., Rappaport, A. R., Herold, M. J., et al. (2012) · Genes & Development · doi:10.1101/gad.182980.111 · Cited by 423
Many players in BCL-2 family affairs
Moldoveanu, T., Follis, A. V., Kriwacki, R. W., & Green, D. R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.006 · Cited by 421
Paclitaxel: What has been done and the challenges remain ahead
Bernabeu, E., Cagel, M., Lagomarsino, E., Moretton, M., & Chiappetta, D. A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.016 · Cited by 413
Molecular mechanisms for tumour resistance to chemotherapy
Pan, S., Li, Z., He, Z., Qiu, J., & Zhou, S. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12581 · Cited by 401
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment: Miniperspective
Waghray, D., & Zhang, Q. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01457 · Cited by 400
Current trends in drug metabolism and pharmacokinetics
Li, Y., Meng, Q., Yang, M., Liu, D., Hou, X., Tang, L., Wang, X., Lyu, Y., Chen, X., Liu, K., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.10.001 · Cited by 391
Binkhathlan, Z., & Lavasanifar, A. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990076 · Cited by 390
Cancer Development, Progression, and Therapy: An Epigenetic Overview
Sarkar, S., Horn, G., Moulton, K., Oza, A., Byler, S., Kokolus, S., & Longacre, M. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141021087 · Cited by 386
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
Self-citationPost-translational modifications of tubulin: pathways to functional diversity of microtubules
Song, Y., & Brady, S. T. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.10.004 · Cited by 376
Microtubule dynamics in vitro are regulated by the tubulin isotype composition.
Panda, D., Miller, H. P., Banerjee, A., Ludueña, R. F., & Wilson, L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11358 · Cited by 374
The binding conformation of Taxol in β-tubulin: A model based on electron crystallographic density
Snyder, J. P., Nettles, J. H., Cornett, B., Downing, K. H., & Nogales, E. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051309398 · Cited by 362
Iwasawa, H., Takita, H., Goto, K., Mansuer, W., Miyashita, T., Schwier, E. F., Ino, A., Shimada, K., & Aiura, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-34894-7 · Cited by 358
What Is Nuclear Factor Kappa B (NF-κB) Doing in and to the Mitochondrion?
Albensi, B. C. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00154 · Cited by 341
Mi, Y.-J., Liang, Y.-J., Huang, H.-B., Zhao, H.-Y., Wu, C.-P., Wang, F., Tao, L.-Y., Zhang, C.-Z., Dai, C.-L., Tiwari, A. K., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0111 · Cited by 337
Self-citationThe role of photodynamic therapy in overcoming cancer drug resistance
Spring, B. Q., Rizvi, I., Xu, N., & Hasan, T. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c4pp00495g · Cited by 335
Schultz, C., Link, A., Leost, M., Zaharevitz, D. W., Gussio, R., Sausville, E. A., Meijer, L., & Kunick, C. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9900570 · Cited by 334
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
Self-citationUse of Epigenetic Drugs in Disease: An Overview
Heerboth, S., Lapinska, K., Snyder, N., Leary, M., Rollinson, S., & Sarkar, S. (2014) · Genetics & Epigenetics · doi:10.4137/geg.s12270 · Cited by 326
Bissery, M.-C., Nohynek, G., Sanderink, G.-J., & Lavelie, F. (1995) · Anti-Cancer Drugs · doi:10.1097/00001813-199506000-00001 · Cited by 323
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
Self-citationPatil, Y. B., Swaminathan, S. K., Sadhukha, T., Ma, L., & Panyam, J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.048 · Cited by 304
Nanotechnology applied to overcome tumor drug resistance
Gao, Z., Zhang, L., & Sun, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.051 · Cited by 303
Pusztai, L., Wagner, P., Ibrahim, N., Rivera, E., Theriault, R., Booser, D., Symmans, F. W., Wong, F., Blumenschein, G., Fleming, D. R., et al. (2005) · Cancer · doi:10.1002/cncr.21227 · Cited by 302
International Review of Cell and Molecular Biology
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/s1937-6448(19)30014-0 · Cited by 296
Patel, N. M., Nozaki, S., Shortle, N. H., Bhat-Nakshatri, P., Newton, T. R., Rice, S., Gelfanov, V., Boswell, S. H., Goulet, R. J., Sledge, G. W., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203768 · Cited by 294
Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets
Kopecka, J., Trouillas, P., Gašparović, A. Č., Gazzano, E., Assaraf, Y. G., & Riganti, C. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100670 · Cited by 291
Self-citationTaxol®: The First Microtubule Stabilizing Agent
Yang, C.-P., & Horwitz, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081733 · Cited by 284
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
Sikic, B. I. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051055 · Cited by 277
The structural modification of natural products for novel drug discovery
Yao, H., Liu, J., Xu, S., Zhu, Z., & Xu, J. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1272757 · Cited by 275
Microtubule-targeting agents and their impact on cancer treatment
Čermák, V., Dostál, V., Jelínek, M., Libusová, L., Kovář, J., Rösel, D., & Brábek, J. (2020) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2020.151075 · Cited by 275
Zhang, H., Xu, H., Ashby, C. R., Assaraf, Y. G., Chen, Z., & Liu, H. (2021) · Medicinal Research Reviews · doi:10.1002/med.21739 · Cited by 270
Self-citationBarbuti, A., & Chen, Z.-S. (2015) · Cancers · doi:10.3390/cancers7040897 · Cited by 269
Self-citationTumoral and tissue‐specific expression of the major human β‐tubulin isotypes
Leandro‐García, L. J., Leskelä, S., Landa, I., Montero‐Conde, C., López‐Jiménez, E., Letón, R., Cascón, A., Robledo, M., & Rodríguez‐Antona, C. (2010) · Cytoskeleton · doi:10.1002/cm.20436 · Cited by 265
Gadadhar, S., Bodakuntla, S., Natarajan, K., & Janke, C. (2017) · Journal of Cell Science · doi:10.1242/jcs.199471 · Cited by 257
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Dong, J., Qin, Z., Zhang, W.-D., Cheng, G., Yehuda, A. G., Ashby, C. R., Chen, Z.-S., Cheng, X.-D., & Qin, J.-J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100681 · Cited by 255
Self-citationDevelopment of inhibitors of ATP-binding cassette drug transporters – present status and challenges
Shukla, S., Wu, C.-P., & Ambudkar, S. V. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.2.205 · Cited by 253
Are tubulin isotypes functionally significant.
Ludueña, R. F. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.5.445 · Cited by 253
Different strategies to overcome multidrug resistance in cancer
Saraswathy, M., & Gong, S. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.06.004 · Cited by 248
Update on taxane development: new analogs and new formulations
Tkaczuk, K., & Yared, J. (2012) · Drug Design, Development and Therapy · doi:10.2147/dddt.s28997 · Cited by 247
Kamath, K., Wilson, L., Cabral, F., & Jordan, M. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414477200 · Cited by 247
Qiu, G.-Z., Jin, M.-Z., Dai, J.-X., Sun, W., Feng, J.-H., & Jin, W.-L. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.05.002 · Cited by 245
Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation
Walczak, H. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008698 · Cited by 242
Nanotechnology in Cancer Drug Delivery and Selective Targeting
Sutradhar, K. B., & Amin, M. L. (2014) · ISRN Nanotechnology · doi:10.1155/2014/939378 · Cited by 241
Overview of Major Classes of Plant-Derived Anticancer Drugs
Amin, A., Gali‐Muhtasib, H. U., Ocker, M., & Schneider‐Stock, R. (2009) · International Journal of Biomedical Science · doi:10.59566/ijbs.2009.5001 · Cited by 241
Wang, J.-Q., Yang, Y., Cai, C.-Y., Teng, Q.-X., Cui, Q., Lin, J., Assaraf, Y. G., & Chen, Z.-S. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100743 · Cited by 241
Self-citationMeng, J., Guo, F., Xu, H., Liang, W., Wang, C., & Yang, X.-D. (2016) · Scientific Reports · doi:10.1038/srep22390 · Cited by 236
Steinbach, D., Sell, W., Voigt, A., Hermann, J., Zintl, F., & Sauerbrey, A. (2002) · Leukemia · doi:10.1038/sj.leu.2402541 · Cited by 226
Overview of P-glycoprotein inhibitors: a rational outlook
Srivalli, K. M. R., & Lakshmi, P. K. (2012) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502012000300002 · Cited by 225
Minotti, A. M., Barlow, S. B., & Cabral, F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)67891-9 · Cited by 221
Reversal of multidrug resistance in cancer cells by pyranocoumarins isolated from Radix Peucedani
Wu, J. Y.-C., Fong, W.-F., Zhang, J.-X., Leung, C.-H., Kwong, H.-L., Yang, M.-S., Li, D., & Cheung, H.-Y. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01946-0 · Cited by 221
Yu, D., Liu, B., Tan, M., Li, J., Wang, S., & Hung, M. (1996) · PubMed · Cited by 220
Burns, T. F., Fei, P., Scata, K. A., Dicker, D. T., & El-Deiry, W. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.16.5556-5571.2003 · Cited by 219
Dendrimers in combination with natural products and analogues as anti-cancer agents
Mignani, S., Rodrigues, J., Tomas, H., Zablocka, M., Shi, X., Caminade, A.-M., & Majoral, J.-P. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00550d · Cited by 219
Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy
Qi, S.-S., Sun, J.-H., Yu, H.-H., & Yu, S.-Q. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1410256 · Cited by 218
A Short Nur77-Derived Peptide Converts Bcl-2 from a Protector to a Killer
Kolluri, S. K., Zhu, X., Zhou, X., Lin, B., Chen, Y., Sun, K., Tian, X., Town, J., Cao, X., Lin, F., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.09.002 · Cited by 217
Taxane anticancer agents: a patent perspective
Ojima, I., Lichtenthal, B., Lee, S., Wang, C., & Wang, X. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1111872 · Cited by 217
Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes
Yardley, D. A. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/137414 · Cited by 216
Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells
Ranganathan, S., Benetatos, C., Colarusso, P., Dexter, D., & Hudes, G. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.91 · Cited by 214
Kinesin motor proteins as targets for cancer therapy
Huszar, D., Theoclitou, M.-E., Skolnik, J., & Herbst, R. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9185-8 · Cited by 206
Rationally designed nanovehicles to overcome cancer chemoresistance
Livney, Y. D., & Assaraf, Y. G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.006 · Cited by 205
Self-citationLiang, Y., Han, H., Liu, L., Duan, Y., Yang, X., Ma, C., Zhu, Y., Han, J., Li, X., & Chen, Y. (2018) · Oncogenesis · doi:10.1038/s41389-018-0107-x · Cited by 205
Genetic and epigenetic aspects of breast cancer progression and therapy.
Byler, S., Goldgar, S., Heerboth, S. A., Leary, M., Housman, G., Moulton, K. L., & Sarkar, S. (2014) · PubMed · Cited by 203
Microtubules: A dynamic target in cancer therapy
Pasquier, E., & Kavallaris, M. (2008) · IUBMB Life · doi:10.1002/iub.25 · Cited by 195
Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
Stengel, C., Newman, S. P., Leese, M. P., Potter, B. V. L., Reed, M. J., & Purohit, A. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605489 · Cited by 192
Li, B., Jiang, J., Assaraf, Y. G., Xiao, H., Chen, Z.-S., & Huang, C. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100720 · Cited by 188
Self-citationOncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy
Pines, G., Köstler, W. J., & Yarden, Y. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.019 · Cited by 187
Nobili, S., Landini, I., Mazzei, T., & Mini, E. (2012) · Medicinal Research Reviews · doi:10.1002/med.20239 · Cited by 182
miRNA-34a is associated with docetaxel resistance in human breast cancer cells
Kastl, L., Brown, I., & Schofield, A. C. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1424-3 · Cited by 174
Patel, N. R., Rathi, A., Mongayt, D., & Torchilin, V. P. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.082 · Cited by 173
Anand, U., Nandy, S., Mundhra, A., Das, N., Pandey, D. K., & Dey, A. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100695 · Cited by 173
Self-citationNew Insight into P-Glycoprotein as a Drug Target
Breier, A., Gibalová, L., Šereš, M., Barančík, M., & Sulová, Z. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152013804487380 · Cited by 171
Marcus, A. I., Peters, U., Thomas, S. L., Garrett, S., Zelnak, A., Kapoor, T. M., & Giannakakou, P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413471200 · Cited by 170
The role of ubiquitin modification in the regulation of p53
Hock, A. K., & Vousden, K. H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.05.022 · Cited by 168
Perplexing Role of P-Glycoprotein in Tumor Microenvironment
Robinson, K., & Tiriveedhi, V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00265 · Cited by 168
Dong, Q. G., Sclabas, G. M., Fujioka, S., Schmidt, C., Peng, B., Wu, T., Tsao, M.-S., Evans, D. B., Abbruzzese, J. L., McDonnell, T. J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205848 · Cited by 166
The Determinants That Govern Microtubule Assembly from the Atomic Structure of GTP-Tubulin
Nawrotek, A., Knossow, M., & Gigant, B. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.07.029 · Cited by 165
Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance
Shahar, N., & Larisch, S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100712 · Cited by 165
Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines
Zhang, H., Guttikonda, S., Roberts, L., Uziel, T., Semizarov, D., Elmore, S. W., Leverson, J. D., & Lam, L. T. (2011) · Oncogene · doi:10.1038/onc.2010.559 · Cited by 164
Plant natural products: from traditional compounds to new emerging drugs in cancer therapy
Ouyang, L., Luo, Y., Tian, M., Zhang, S. ‐., Lu, R., Wang, J. ‐., Kasimu, R., & Li, X. (2014) · Cell Proliferation · doi:10.1111/cpr.12143 · Cited by 163
Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics
Lin, G., Mi, P., Chu, C., Zhang, J., & Liu, G. (2016) · Advanced Science · doi:10.1002/advs.201600134 · Cited by 163
Huang, Y., Ray, S., Reed, J. C., Ibrado, A. M., Tang, C., Nawabi, A., & Bhalla, K. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005777219997 · Cited by 162
Ploussard, G., Terry, S., Maillé, P., Allory, Y., Sirab, N., Kheuang, L., Soyeux, P., Nicolaiew, N., Coppolani, E., Paule, B., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1447 · Cited by 161
Tubulin Post-Translational Modifications and Microtubule Dynamics
Wloga, D., Joachimiak, E., & Fabczak, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102207 · Cited by 161
Bcl-2 Down-Regulation Is a Novel Mechanism of Paclitaxel Resistance
Ferlini, C., Raspaglio, G., Mozzetti, S., Distefano, M., Filippetti, F., Martinelli, E., Ferrandina, G., Gallo, D., Ranelletti, F. O., & Scambia, G. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.1.51 · Cited by 160
Overcoming Multidrug Resistance in Cancer: Clinical Studies of P-Glycoprotein Inhibitors
Coley, H. M. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_15 · Cited by 160
Phytochemicals as Potential Anticancer Drugs: Time to Ponder Nature’s Bounty
Ashraf, M. A. (2020) · BioMed Research International · doi:10.1155/2020/8602879 · Cited by 160
Zhang, C. C., Yang, J.-M., White, E., Murphy, M., Levine, A., & Hait, W. N. (1998) · Oncogene · doi:10.1038/sj.onc.1201658 · Cited by 159
Martello, L. A., Verdier‐Pinard, P., Shen, H. J., He, L., Torres, K. E., Orr, G. A., & Horwitz, S. B. (2003) · PubMed · Cited by 158
Lhommé, C., Joly, F., Walker, J. L., Lissoni, A. A., Nicoletto, M. O., Manikhas, G. M., Baekelandt, M. M. O., Gordon, A. N., Fracasso, P. M., Mietlowski, W. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9807 · Cited by 158
Hari, M., Loganzo, F., Annable, T., Tan, X., Musto, S., Morilla, D. B., Nettles, J. H., Snyder, J. P., & Greenberger, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0190 · Cited by 156
Plant derived anticancer agents: A green approach towards skin cancers
Ijaz, S., Akhtar, N., Khan, S., Hameed, A., Irfan, M. I., Arshad, M. A., Ali, S., & Asrar, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.113 · Cited by 152
Overexpression of Kinesins Mediates Docetaxel Resistance in Breast Cancer Cells
De, S., Cipriano, R., Jackson, M. W., & Stark, G. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1224 · Cited by 151
Wei, S., Dong, K., Fang, L., Wang, X., Li, B., Shen, J., Zhang, Q., Wang, R., & Zhang, H. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0697-7 · Cited by 150
Kütük, Ö., & Letai, A. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1418 · Cited by 146
Takeda, M., Mizokami, A., Mamiya, K., Li, Y. Q., Zhang, J., Keller, E. T., & Namiki, M. (2007) · The Prostate · doi:10.1002/pros.20581 · Cited by 146
Lu, X., Cao, X., Zhu, Y., Wu, Z., Zhuang, X., Shao, M., Xu, Q., Zhou, Y., Ji, H., Lu, Q.-R., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0428-x · Cited by 146
Sui, H. X., Fan, Z.-Z., & Li, Q. (2012) · Journal of International Medical Research · doi:10.1177/147323001204000204 · Cited by 145
Post-translational modifications of tubulin
Magiera, M. M., & Janke, C. (2014) · Current Biology · doi:10.1016/j.cub.2014.03.032 · Cited by 145
Haber, M., Burkhart, C. A., Regl, D. L., Madafiglio, J., Norris, M. D., & Horwitz, S. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.52.31269 · Cited by 139
Iravani, S., & Varma, R. S. (2019) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.9b00954 · Cited by 136
He, L., Yang, C. P., & Horwitz, S. B. (2001) · PubMed · Cited by 131
Ricker, J. L., Chen, Z., Yang, X. P., Pribluda, V. S., Swartz, G. M., & Waes, C. V. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1393 · Cited by 129
Self-citationTranscription Factor NF-κB: An Update on Intervention Strategies
Panday, A., Inda, M. E., Bagam, P., Sahoo, M. K., Osorio, D., & Batra, S. (2016) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0405-y · Cited by 126
Bio-inspired drug delivery systems: an emerging platform for targeted cancer therapy
Neubi, G. M. N., Opoku‐Damoah, Y., Gu, X., Han, Y., Zhou, J., & Ding, Y. (2018) · Biomaterials Science · doi:10.1039/c8bm00175h · Cited by 126
Cao, Y., Yu, J., Liu, T., Yang, K.-X., Yang, L.-Y., Chen, Q., Shi, F., Hao, J., Cai, Y., Wang, M., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0068-6 · Cited by 122
Nanomedicine to target multidrug resistant tumors
Lepeltier, É., Rijo, P. M., Rizzolio, F., Popovtzer, R., Petrikaitė, V., Assaraf, Y. G., & Passirani, C. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100704 · Cited by 121
Self-citationAk, B., Roach, M., Trcka, P. P., & Ludueña, R. F. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42811-6 · Cited by 120
Brotin, É., Meryet‐Figuière, M., Simonin, K., Duval, R. E., Villedieu, M., Leroy‐Dudal, J., Saison-Behmoaras, E., Gauduchon, P., Denoyelle, C., & Poulain, L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24787 · Cited by 120
Wang, Y., Qu, Y., Niu, X. L., Sun, W. J., Zhang, X. L., & Li, L. Z. (2011) · Cytokine · doi:10.1016/j.cyto.2011.06.005 · Cited by 120
P53 vs NF-κB: the role of nuclear factor-kappa B in the regulation of p53 activity and vice versa
Carrà, G., Lingua, M. F., Maffeo, B., Taulli, R., & Morotti, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03524-9 · Cited by 120
Hypoxia-inducible factor-1α induces multidrug resistance protein in colon cancer
Lv, Y., Zhao, S., Han, J., Zheng, L., Yang, Z., & Zhao, L. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s82835 · Cited by 119
Montgomery, B., Guzman, J., O’Rourke, D. M., & Stahl, W. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000966200 · Cited by 115
Thermodynamics of ligand-induced assembly of tubulin
Díaz, J. F., Menéndez, M., & Andreu, J. M. (1993) · Biochemistry · doi:10.1021/bi00089a023 · Cited by 114
Fanale, D., Bronte, G., Passiglia, F., Calò, V., Castiglia, M., Piazza, F. D., Barraco, N., Cangemi, A. G., Catarella, M. T., Insalaco, L., et al. (2015) · Analytical Cellular Pathology · doi:10.1155/2015/690916 · Cited by 112
Inhibition of P-Glycoprotein-Mediated Paclitaxel Resistance by Reversibly Linked Quinine Homodimers
Pires, M. M., Emmert, D., Hrycyna, C. A., & Chmielewski, J. A. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.050492 · Cited by 112
A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology
Acker, T., & Plate, K. H. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0355-1 · Cited by 112
Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance.
Vasey, P. A., Jones, N. A., Jenkins, S., Dive, C., & Brown, R. E. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09612-9 · Cited by 110
Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters
Eid, S. Y., El-Readi, M. Z., & Wink, M. (2012) · Phytomedicine · doi:10.1016/j.phymed.2012.05.010 · Cited by 110
Alli, E., Yang, J., Ford, J. M., & Hait, W. N. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.029702 · Cited by 109
Mitotic catastrophe and cancer drug resistance: A link that must to be broken
Denisenko, T. V., Sorokina, I. V., Gogvadze, V., & Zhivotovsky, B. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.002 · Cited by 108
Alterations of β‐tubulin isotypes in breast cancer cells resistant to docetaxel
Shalli, K., Brown, I. M., Heys, S. D., & Schofield, C. A. (2005) · The FASEB Journal · doi:10.1096/fj.04-3178fje · Cited by 107
Chun, E., & Lee, K. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.118 · Cited by 105
BCRP mRNA expression v. clinical outcome in 40 adult AML patients
Uggla, B., Ståhl, E., Wågsäter, D., Paul, C., Karlsson, M. G., Sirsjö, A., & Tidefelt, U. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.06.004 · Cited by 103
Verdier‐Pinard, P., Wang, F., Martello, L. A., Burd, B., Orr, G. A., & Horwitz, S. B. (2003) · Biochemistry · doi:10.1021/bi027293o · Cited by 103
Arceci, A., Bonacci, T., Wang, X., Stewart, K. G., Damrauer, J. S., Hoadley, K. A., & Emanuele, M. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.054 · Cited by 102
The Roles of β-Tubulin Mutations and Isotype Expression in Acquired Drug Resistance
Huzil, J. T., Chen, K., Kurgan, L., & Tuszyński, J. A. (2007) · Cancer Informatics · doi:10.1177/117693510700300028 · Cited by 101
Lin, H.-L., Liu, T.-Y., Wu, C.-W., & Chi, C.-W. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690710 · Cited by 100
Zhang, C. C., Yang, J., Bash-Babula, J., White, E., Murphy, M. E., Levine, A. J., & Hait, W. N. (1999) · PubMed · Cited by 100
Seiden, M. V., Swenerton, K. D., Matulonis, U. A., Campos, S., Rose, P. G., Batist, G., Ette, E., Garg, V., Fuller, A., Harding, M. W., et al. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6762 · Cited by 98
Human Mutations That Confer Paclitaxel Resistance
Yin, S., Bhattacharya, R., & Cabral, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0674 · Cited by 98
Levallet, G., Bergot, E., Antoine, M., Créveuil, C., Santos, A. O., Beau-Faller, M., de Fraipont, F., Brambilla, E. M., Levallet, J., Morin, F., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0899 · Cited by 98
Chen, T., Wang, C., Liu, Q., Meng, Q., Sun, H., Huo, X., Sun, P., Peng, J., Liu, Z., Yang, X., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.987062 · Cited by 98
Jiang, Y., Liu, M., Liu, H., & Liu, S. (2020) · Phytochemistry Reviews · doi:10.1007/s11101-020-09673-w · Cited by 98
Bcl-2 Mediates Chemoresistance in Matched Pairs of Primary Eμ-myc Lymphomas in Vivo
Schmitt, C. A., & Lowe, S. W. (2001) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2000.0372 · Cited by 97
Fracasso, P. M., Brady, M. F., Moore, D. H., Walker, J. L., Rose, P. G., Letvak, L. A., Grogan, T. M., & McGuire, W. P. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.2975 · Cited by 95
wang, L., Li, H., Ren, Y., Zou, S., Fang, W., Jiang, X., Li, J., Li, M., Liu, X., Yuan, X., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.328 · Cited by 95
Mohammed, M. J., Anand, U., Altemimi, A. B., Tripathi, V. S., Guo, Y., & Singh, A. P. (2021) · Plants · doi:10.3390/plants10010164 · Cited by 95
Self-citationBanerjee, A. K. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00269-3 · Cited by 94
Baek, J.-S., & Cho, C. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.12.018 · Cited by 92
Nanoparticle-based combination drug delivery systems for synergistic cancer treatment
Choi, J. Y., Thapa, R. K., Yong, C. S., & Kim, J. O. (2016) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-016-0252-1 · Cited by 91
Zhang, J., Wang, L., Chan, H. F., Xie, W., Chen, S., He, C., Wang, Y., & Chen, M. (2017) · Scientific Reports · doi:10.1038/srep46057 · Cited by 91
Research works printed but not linked: 43
- Bevis, 2014, Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study, J. Reprod. Med., 59, 113
- Cai, 2014, Salvianolic acid A reverses paclitaxel resistance in human breast cancer MCF-7 cells via targeting the expression of transgelin 2 and attenuating PI3 K/Akt pathway, Phytomedicine, 21, 1725, 10.1016/j.phymed.2014.08.007 · doi:10.1016/j.phymed.2014.08.007
- Cao, 2013, Characterization of flavonoids from Dryopteris erythrosora and evaluation of their antioxidant, anticancer and acetylcholinesterase inhibition activities, Food Chem. Toxicol., 51, 242, 10.1016/j.fct.2012.09.039 · doi:10.1016/j.fct.2012.09.039
- Dong, 2017, Inhibitory effect of Shenqi Fuzheng injection combined with docetaxel on lung cancer cells, J. Zhejiang Univ. Sci. B, 18, 76, 10.1631/jzus.B1600357 · doi:10.1631/jzus.b1600357
- Elnaggar, 2017, Self-emulsifying preconcentrates of daidzein–phospholipid complex: design, in vitro and in vivo appraisal, Nanomedicine, 12, 893, 10.2217/nnm-2016-0387 · doi:10.2217/nnm-2016-0387
- Guntur, 2010, Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro, Anticancer Res., 30, 3557
- Guo, 2017, Research progress in reversal of tumor multi-drug resistance via natural products, Anticancer Agents Med. Chem., 17, 1466, 10.2174/1871520617666171016105704 · doi:10.2174/1871520617666171016105704
- Haider, 2019, Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018), Expert Opin. Ther. Pat., 29, 623, 10.1080/13543776.2019.1648433 · doi:10.1080/13543776.2019.1648433
- Han, 2013, Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2, Cancer Biother. Radiopharm., 28, 398
- He, 2014, The relationships between the chemosensitivity of human gastric cancer to paclitaxel and the expressions of class III β-tubulin, MAPT, and survivin, Med. Oncol., 31, 950, 10.1007/s12032-014-0950-3 · doi:10.1007/s12032-014-0950-3
- Hsieh, 2014, Psoralen reverses docetaxel-induced multidrug resistance in A549/D16 human lung cancer cells lines, Phytomedicine, 21, 970, 10.1016/j.phymed.2014.03.008 · DOI
- Huo, 2021, A combined bioinformatic and nanoparticle-based study reveal the role of ABCG2 in the resistance of breast Cancer, Recent Pat. Anticancer Drug Discov.
- Kars, 2013, Exploring a natural MDR reversal agent: potential of medicinal food supplement Nerium oleander leaf distillate, Asian Pac. J. Trop. Biomed., 3, 644, 10.1016/S2221-1691(13)60130-6 · doi:10.1016/s2221-1691(13)60130-6
- Kars, 2013, Paclitaxel resistance in MCF-7/Pac cell line is reversed successfully by Saikosaponin A and saikosaponin D, Int. J. Hematol. Oncol., 24, 227, 10.4999/uhod.13009 · doi:10.4999/uhod.13009
- Kawami, 2010, Effect of Thai plant extracts on P-glycoprotein function and viability in paclitaxel-resistant HepG2 cells, Drug Metab. Pharmacokinet., 25, 155, 10.2133/dmpk.25.155 · doi:10.2133/dmpk.25.155
- Kovalev, 2013, Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer, Exp. Oncol., 35, 287
- Lee, 2018, 10-Phenyltriazoyl artemisinin is a novel P-glycoprotein inhibitor that suppresses the overexpression and function of P-glycoprotein, Curr. Pharm. Des., 24, 5590, 10.2174/1381612825666190222155700 · doi:10.2174/1381612825666190222155700
- Li, 2018, Curcumin inhibits proliferation, migration, invasion and promotes apoptosis of retinoblastoma cell lines through modulation of miR-99a and JAK/STAT pathway, BMC Cancer, 18, 1, 10.1186/s12885-018-5130-y · doi:10.1186/s12885-018-5130-y
- Li, 2020, Activity and mechanism of flavokawain A in inhibiting permeability glycoprotein expression in paclitaxel resistance of lung cancer, Oncol. Lett., 19, 379
- Limtrakul, 2007, Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells, Phytomedicine, 14, 381, 10.1016/j.phymed.2007.03.006 · doi:10.1016/j.phymed.2007.03.006
- Liu, 2014, Compound injection of shenqi as a reversal drug on docetaxel resistant human lung adenocarcinoma cell A549/DTX, Vol. 926, 1054
- Liu, 2020, Identification of a lathyrane-type diterpenoid EM-E-11-4 as a novel paclitaxel resistance reversing agent with multiple mechanisms of action, Aging (Albany NY), 12, 3713, 10.18632/aging.102842 · doi:10.18632/aging.102842
- Malesinski, 2015, Stathmin potentiates vinflunine and inhibits Paclitaxel activity, PLoS One, 10, e0128704, 10.1371/journal.pone.0128704 · doi:10.1371/journal.pone.0128704
- Markman, 2000, Phase I trial of paclitaxel plus megestrol acetate in patients with paclitaxel-refractory ovarian cancer, Clin. Cancer Res., 6, 4201
- Matthews, 2006, MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia, Leuk. Lymphoma, 47, 2308, 10.1080/10428190600881421 · doi:10.1080/10428190600881421
- Peña-Solórzano, 2018, Tariquidar-related chalcones and ketones as ABCG2 modulators, ACS Med. Chem. Lett., 9, 854, 10.1021/acsmedchemlett.8b00289 · doi:10.1021/acsmedchemlett.8b00289
- Reinecke, 2000, Multidrug resistance phenotype and paclitaxel (taxol) sensitivity in human renal carcinoma cell lines of different histologic types, Cancer Invest., 18, 614, 10.3109/07357900009032828 · doi:10.3109/07357900009032828
- Ren, 2016, Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer, Biochim. Biophys. Acta, 1866, 266
- Ren, 2017, Cardiac glycoside constituents of Streblus asper with potential antineoplastic activity, J. Nat. Prod., 80, 648, 10.1021/acs.jnatprod.6b00924 · doi:10.1021/acs.jnatprod.6b00924
- Revalde, 2015, Heterocycliccyclohexanone monocarbonyl analogs of curcumin can inhibit the activity ofATP-binding cassette transporters in cancer multidrug resistance, Biochem. Pharmacol., 93, 305, 10.1016/j.bcp.2014.12.012 · doi:10.1016/j.bcp.2014.12.012
- Russo, 2019, Toward a personalized use of paclitaxel, Recent Pat. Anticancer Drug Discov., 14, 296, 10.2174/157489281404191220161014 · doi:10.2174/157489281404191220161014
- Schroeder, 2019, Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer, BMC Cancer, 19, 193, 10.1186/s12885-019-5390-1 · doi:10.1186/s12885-019-5390-1
- Shehata, 2016, Self-emulsifying phospholipid pre-concentrates (SEPPs) for improved oral delivery of the anti-cancer genistein: development, appraisal and ex-vivo intestinal permeation, Int. J. Pharm., 511, 745, 10.1016/j.ijpharm.2016.07.078 · doi:10.1016/j.ijpharm.2016.07.078
- Sootichote, 2018, Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8, BMC Cancer, 18, 231, 10.1186/s12885-018-4155-6 · doi:10.1186/s12885-018-4155-6
- Tan, 2012, Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer, Breast Cancer Res. Treat., 131, 849, 10.1007/s10549-011-1500-8 · doi:10.1007/s10549-011-1500-8
- Twentyman, 1997, Transport proteins in drug resistance: biology and approaches to circumvention, J. Intern. Med. Suppl., 740, 133, 10.1111/joim.1997.242.s740.133 · doi:10.1111/joim.1997.242.s740.133
- Vogelstein, 2010, p53: the most frequently altered gene in human cancers, Nat. Educ., 3, 6
- Watanabe, 2013, BCL 2 and BCL xL are key determinants of resistance to antitubulin chemotherapeutics in melanoma cells, Exp. Dermatol., 22, 518, 10.1111/exd.12185 · doi:10.1111/exd.12185
- Wu, 2014, A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells, Cell Oncol. (Dordr)., 37, 53, 10.1007/s13402-013-0163-3 · doi:10.1007/s13402-013-0163-3
- Yang, 2011, Reversal of multidrug resistance in human breast cancer cells by Curcuma wenyujin and Chrysanthemum indicum, Phytomedicine, 18, 710, 10.1016/j.phymed.2010.11.017 · doi:10.1016/j.phymed.2010.11.017
- Yu, 2018, Soluble resistance-related calcium-binding protein in cancers, Clin. Chim. Acta, 486, 369, 10.1016/j.cca.2018.08.034 · doi:10.1016/j.cca.2018.08.034
- Zhao, 2012, YHHU0895, a novel synthetic small-molecule microtubule-destabilizing agent, effectively overcomes P-glycoprotein-mediated tumor multidrug resistance, Cancer Lett., 314, 54, 10.1016/j.canlet.2011.09.013 · doi:10.1016/j.canlet.2011.09.013
- Zhou, 2009, Cepharanthine is a potent reversal agent for MRP7 (ABCC10)-mediated multidrug resistance, Biochem. Pharmacol., 77, 993, 10.1016/j.bcp.2008.12.005 · doi:10.1016/j.bcp.2008.12.005
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Self-citationAnticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Hanssen, K. M., Haber, M., & Fletcher, J. I. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100795 · Cited by 102
Cellular landscaping of cisplatin resistance in cervical cancer
Bhattacharjee, R., Dey, T., Kumar, L., Kar, S., Sarkar, R., Ghorai, M., Malik, S., Jha, N. K., Vellingiri, B., Kesari, K. K., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113345 · Cited by 93
Self-citationPFOS and Its Commercial Alternative, 6:2 Cl-PFESA, Induce Multidrug Resistance in Pancreatic Cancer
Hong, J., Du, K., Zhang, W., Jiang, Y., Yu, H., Pan, T., Wu, T., Zhao, L., Du, W., Zheng, S.-S., et al. (2024) · Environmental Science & Technology · doi:10.1021/acs.est.4c08669 · Cited by 16
Metadata
- Authors
- Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 55
- Pages
- 100754
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W3133748827
- Cited by
- 253
- References
- 340
- FWCI
- 11.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Presidency University
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.